Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

Key Points

• Y-mAbs Therapeutics has been downgraded by Brookline Capital Management from a "strong-buy" to a "hold" rating, reflecting a shift in analyst sentiment.
• Multiple firms have set target prices for Y-mAbs stock, ranging from $3.00 by Bank of America to $8.60 by both Cantor Fitzgerald and Morgan Stanley, indicating a cautious outlook for the company.
• The stock has experienced significant fluctuations, with a 52-week low of $3.55 and a high of $16.11, and currently holds an average analysts' rating of "hold" with a target price of $11.16.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was downgraded by Brookline Capital Management from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday,Zacks.com reports.

A number of other research firms have also issued reports on YMAB. Cantor Fitzgerald set a $8.60 target price on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a report on Tuesday. Bank of America lowered shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a report on Tuesday, April 22nd. Morgan Stanley set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday. Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $26.00 to $8.60 in a report on Tuesday. Finally, Jones Trading restated a "hold" rating on shares of Y-mAbs Therapeutics in a report on Tuesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $11.16.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $8.52 on Tuesday. The firm has a market cap of $385.82 million, a PE ratio of -13.31 and a beta of 0.57. Y-mAbs Therapeutics has a 52-week low of $3.55 and a 52-week high of $16.11. The company's 50 day moving average is $4.79 and its two-hundred day moving average is $4.92.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative return on equity of 30.59%. On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brooklyn Investment Group grew its position in Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares during the last quarter. CWM LLC grew its position in Y-mAbs Therapeutics by 203.0% during the 2nd quarter. CWM LLC now owns 7,121 shares of the company's stock worth $32,000 after purchasing an additional 4,771 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Y-mAbs Therapeutics during the 4th quarter worth $46,000. Los Angeles Capital Management LLC purchased a new position in Y-mAbs Therapeutics during the 2nd quarter worth $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Y-mAbs Therapeutics during the 1st quarter worth $49,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.